Eisai Licenses E6020 Vaccine Adjuvant to Sanofi Pasteur SA
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that on October 24 it signed license and supply agreements with Sanofi Pasteur SA (Headquarters: Lyon, France, President & CEO: David J Williams) for the use of Eisai's E6020 as an adjuvant to enhance the immune response to a broad range of vaccines.
As part of the agreement, Sanofi Pasteur obtained a non-exclusive license to incorporate the E6020 adjuvant in vaccines for use throughout all geographical regions. Sanofi Pasteur plans to test E6020, supplied by Eisai, in the development of new vaccine products. Under the terms of the agreement, Eisai will receive up-front license fees, success-based milestone payments and royalties from product sales.
E6020 is a synthetic substance that was discovered at the Eisai Research Institute of Boston, Inc. E6020 is a TLR-4 (Toll-like receptor-4) agonist that stimulates the host's natural immunity. It can be incorporated into various vaccines and is expected to enhance their effectiveness.
Sanofi Pasteur S.A. is a pharmaceutical company that specializes in developing and providing a broad range of vaccines against bacteria and viruses. In the future, as the need for vaccines increases worldwide, E6020 is expected to make significant contributions towards vaccine treatments.
<Notes to Editors>